Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Omnitrope

Omnitrope 5 mg/1.5 ml solution for injection in cartridge Omnitrope 10 mg/1.5 ml solution for injection in cartridge · Abschnitt 4.5 · PDF-Seite 8

HOS-114160 · Präparat HOS-094049

Growth hormone decreases the conversion of cortisone to cortisol and may unmask previously undiscovered central hypoadrenalism or render low glucocorticoid replacement doses ineffective (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cortisone (HOS-114161)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-08-05T09:51:00Z · SHA-256 04942aef939a5be534d028c06f29787f4c372e13feced9592a735ee00dee6200 · Passage f2f7a1d890d01c8f92331161aad05b6fae7667ae3ed00544098f17868b6b6037 · Zeichen 240–444 im Abschnitt

Wechselwirkungen · Omnitrope

Omnitrope 5 mg/1.5 ml solution for injection in cartridge Omnitrope 10 mg/1.5 ml solution for injection in cartridge Omnitrope 15 mg/1.5 ml solution for injection in cartridge · Abschnitt 4.5 · PDF-Seite 23

HOS-114194 · Präparat HOS-094049

Growth hormone decreases the conversion of cortisone to cortisol and may unmask previously undiscovered central hypoadrenalism or render low glucocorticoid replacement doses ineffective (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cortisone (HOS-114161)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-08-05T09:51:00Z · SHA-256 04942aef939a5be534d028c06f29787f4c372e13feced9592a735ee00dee6200 · Passage f2f7a1d890d01c8f92331161aad05b6fae7667ae3ed00544098f17868b6b6037 · Zeichen 240–444 im Abschnitt

Wechselwirkungen · Advagraf

Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 11–12

HOS-116820 · Präparat HOS-094481

11 Drug/Substance Class or Drug interaction effect Recommendations concerning Name co-administration In vitro the following May increase tacrolimus whole Monitor tacrolimus whole substances have been shown blood trough concentrations and blood trough concentrations to be potential inhibitors of increase the risk of serious adverse and reduce tacrolimus dose if tacrolimus metabolism: reactions (e.g., neurotoxicity, QT needed [see section 4.2]. bromocriptine, cortisone, prolongation) [see section 4.4]. Monitor renal function, ECG dapsone, ergotamine, for QT prolongation, and other gestodene, lidocaine, side effects closely. mephenytoin, midazolam, nilvadipine, norethisterone, quinidine, tamoxifen Strong CYP3A4 inducers: May decrease tacrolimus whole It is recommended that rifampicin, phenytoin, blood trough concentrations and concomitant use should be carbamazepine, apalutamide, increase the risk of rejection [see avoided. If unavoidable, enzalutamide, mitotane, or section 4.4]. patients may require an St. John’s wort (Hypericum Maximal effect on tacrolimus blood increase in tacrolimus dose. perforatum) concentrations may be achieved 1-2 Changes in tacrolimus dose weeks after co-administration. The should be individualized and effect may remain 1-2 weeks after adjusted as needed based on completion of the treatment. tacrolimus trough concentrations, which should be assessed at initiation, monitored frequently throughout (starting within the first few days) and re- evaluated on and after completion of the CYP3A4 inducer. After use of the CYP3A4 inducer has ended, tacrolimus dose may need to be adjusted gradually. Monitor graft function closely. Moderate CYP3A4 inducers: May decrease tacrolimus whole Monitor tacrolimus whole metamizole, phenobarbital, blood trough concentrations and blood trough concentrations isoniazid, rifabutin, increase the risk of rejection [see and increase tacrolimus dose if efavirenz, etravirine, section 4.4]. needed [see section 4.2]. nevirapine; weak CYP3A4 Monitor graft function closely. inducers: flucloxacillin

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cortisone (HOS-114161) phenobarbital (HOS-085617) lidocaine (HOS-108866) carbamazepine (HOS-085618) rifabutin (HOS-086262) apalutamide (HOS-086212) tamoxifen (HOS-088380) quinidine (HOS-085593) etravirine (HOS-088088) mephenytoin (HOS-109801) mitotane (HOS-112479) bromocriptine (HOS-090620) efavirenz (HOS-087947) nilvadipine (HOS-116826) gestodene (HOS-116824) nevirapine (HOS-088064) ergotamine (HOS-086154) isoniazid (HOS-088590) dapsone (HOS-088141) phenytoin (HOS-084531) enzalutamide (HOS-116829) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 9f68b7412442537a87ae5cc4a11a2083ae7ee1d4f84bacfd72b3336085546560 · Zeichen 8467–12012 im Abschnitt

Wechselwirkungen · Modigraf

Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 11–12

HOS-209751 · Präparat HOS-154375

11 Drug/Substance Class or Drug interaction effect Recommendations concerning co- Name administration The effect on tacrolimus blood concentrations may remain for several days after co-administration is completed. Moderate or weak CYP3A4 May increase tacrolimus Monitor tacrolimus whole blood inhibitors: whole blood trough trough concentrations frequently, antifungal agents (e.g., concentrations and increase starting within the first few days fluconazole, isavuconazole, the risk of serious adverse of co-administration. Reduce clotrimazole, miconazole), reactions (e.g., neurotoxicity, tacrolimus dose if needed [see the macrolide antibiotics QT prolongation) [see section 4.2]. Monitor renal (e.g., azithromycin), calcium section 4.4]. A rapid increase function, ECG for QT channel blockers (e.g., in tacrolimus level may prolongation, and other side nifedipine, nicardipine, occur. effects closely. diltiazem, verapamil), amiodarone, danazol, ethinylestradiol, lansoprazole, omeprazole, the HCV antivirals elbasvir/grazoprevir and glecaprevir/pibrentasvir, the CMV antiviral letermovir, and the tyrosine kinase inhibitors nilotinib, crizotinib and imatinib and (Chinese) herbal remedies containing extracts of Schisandra sphenanthera In vitro the following May increase tacrolimus Monitor tacrolimus whole blood substances have been shown whole blood trough trough concentrations and reduce to be potential inhibitors of concentrations and increase tacrolimus dose if needed [see tacrolimus metabolism: the risk of serious adverse section 4.2]. bromocriptine, cortisone, reactions (e.g., neurotoxicity, Monitor renal function, ECG for dapsone, ergotamine, QT prolongation) [see QT prolongation, and other side gestodene, lidocaine, section 4.4]. effects closely. mephenytoin, midazolam, nilvadipine, norethisterone, quinidine, tamoxifen Strong CYP3A4 inducers: May decrease tacrolimus It is recommended that rifampicin, phenytoin whole blood trough concomitant use should be carbamazepine, apalutamide, concentrations and increase avoided. If unavoidable, patients enzalutamide, mitotane or St. the risk of rejection [see may require an increase in John’s wort (Hypericum section 4.4]. tacrolimus dose. Changes in perforatum) Maximal effect on tacrolimus tacrolimus dose should be blood concentrations may be individualized and adjusted as achieved 1-2 weeks after co- needed based on tacrolimus administration. The effect trough concentrations, which may remain 1-2 weeks after should be assessed at initiation, completion of the treatment. monitored frequently throughout (starting within the first few days) and re-evaluated on and after completion of the CYP3A4 inducer. After use of the CYP3A4 inducer has ended, tacrolimus

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) diltiazem (HOS-086288) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) cortisone (HOS-114161) nicardipine (HOS-090619) pibrentasvir (HOS-086298) lidocaine (HOS-108866) carbamazepine (HOS-085618) crizotinib (HOS-116818) apalutamide (HOS-086212) tamoxifen (HOS-088380) quinidine (HOS-085593) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) mephenytoin (HOS-109801) calcium (HOS-085615) imatinib (HOS-110212) grazoprevir (HOS-108815) danazol (HOS-085473) mitotane (HOS-112479) fluconazole (HOS-087945) bromocriptine (HOS-090620) nilvadipine (HOS-116826) gestodene (HOS-116824) ergotamine (HOS-086154) amiodarone (HOS-085596) tyrosine (HOS-108875) dapsone (HOS-088141) phenytoin (HOS-084531) enzalutamide (HOS-116829) nilotinib (HOS-086218) miconazole (HOS-115630) midazolam (HOS-086167) omeprazole (HOS-085912) verapamil (HOS-090602)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 1e7cc303a6d0d182851c23281c6a79a17f96d714a9cddc0ab3d6ada78ab947ab · Zeichen 6985–10993 im Abschnitt

Wechselwirkungen · Tacforius

Tacforius 0.5 mg prolonged-release hard capsules Tacforius 1 mg prolonged-release hard capsules Tacforius 3 mg prolonged-release hard capsules Tacforius 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 12–13

HOS-139170 · Präparat HOS-098290

12 Drug/Substance Class or Drug interaction effect Recommendations concerning Name co-administration In vitro the following May increase tacrolimus whole Monitor tacrolimus whole substances have been shown blood trough concentrations and blood trough concentrations to be potential inhibitors of increase the risk of serious adverse and reduce tacrolimus dose if tacrolimus metabolism: reactions (e.g., neurotoxicity, QT needed (see section 4.2). bromocriptine, cortisone, prolongation) (see section 4.4). Monitor renal function, ECG dapsone, ergotamine, for QT prolongation, and other gestodene, lidocaine, side effects closely. mephenytoin, midazolam, nilvadipine, norethisterone, quinidine, tamoxifen. Strong CYP3A4 inducers: May decrease tacrolimus whole It is recommended that rifampicin, phenytoin, blood trough concentrations and concomitant use should be carbamazepine, apalutamide, increase the risk of rejection (see avoided. If unavoidable, enzalutamide, mitotane, or St. section 4.4). patients may require an John’s wort (Hypericum Maximal effect on tacrolimus blood increase in tacrolimus dose. perforatum) concentrations may be achieved 1-2 Changes in tacrolimus dose weeks after co-administration. The should be individualized and effect may remain 1-2 weeks after adjusted as needed based on completion of the treatment. tacrolimus trough concentrations, which should be assessed at initiation, monitored frequently throughout (starting within the first few days) and re- evaluated on and after completion of the CYP3A4 inducer. After use of the CYP3A4 inducer has ended, tacrolimus dose may need to be adjusted gradually. Monitor graft function closely. Moderate CYP3A4 inducers: May decrease tacrolimus whole Monitor tacrolimus whole metamizole, phenobarbital, blood trough concentrations and blood trough concentrations isoniazid, rifabutin, efavirenz, increase the risk of rejection (see and increase tacrolimus dose if etravirine, nevirapine section 4.4). needed (see section 4.2). Weak CYP3A4 inducers: Monitor graft function closely. flucloxacillin Caspofungin May decrease tacrolimus whole Monitor tacrolimus whole blood trough concentrations and blood trough concentrations increase the risk of rejection. and increase tacrolimus dose if Mechanism of interaction has not needed (see section 4.2). been confirmed. Monitor graft function closely. Cannabidiol (P-gp inhibitor) There have been reports of Tacrolimus and cannabidiol increased tacrolimus blood levels should be co-administered with during concomitant use of caution, closely monitoring for tacrolimus with cannabidiol. This side effects. Monitor may be due to inhibition of tacrolimus whole blood trough intestinal P-glycoprotein, leading to concentrations and adjust the increased bioavailability of tacrolimus dose if needed (see tacrolimus. sections 4.2 and 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cortisone (HOS-114161) caspofungin (HOS-109306) phenobarbital (HOS-085617) lidocaine (HOS-108866) carbamazepine (HOS-085618) rifabutin (HOS-086262) apalutamide (HOS-086212) tamoxifen (HOS-088380) quinidine (HOS-085593) etravirine (HOS-088088) mephenytoin (HOS-109801) cannabidiol (HOS-090609) mitotane (HOS-112479) bromocriptine (HOS-090620) efavirenz (HOS-087947) nilvadipine (HOS-116826) gestodene (HOS-116824) nevirapine (HOS-088064) ergotamine (HOS-086154) isoniazid (HOS-088590) dapsone (HOS-088141) phenytoin (HOS-084531) enzalutamide (HOS-116829) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-05-08T17:10:00Z · SHA-256 bf71e479a3104e9d8dd9aede574f2baf87c2d76cd8cc9266ee2ef92ed475dc55 · Passage fa1f35020c5c33f04f1dedfbde5310972baf1c60d65f0f37f47f320487c85aab · Zeichen 8700–13685 im Abschnitt

Wechselwirkungen · Sogroya

Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 8

HOS-144007 · Präparat HOS-099084

Growth hormone decreases the conversion of cortisone to cortisol and may unmask previously undiscovered central hypoadrenalism or render low glucocorticoid replacement doses ineffective, see section 4.4.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cortisone (HOS-114161)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-04T11:30:00Z · SHA-256 eaf5e4dab533bfd4c803b9bbde965757b0299ce4be51c90d44a29cb540844a53 · Passage 7d829f0db504de14d41addafe5f0d63335cb49b9449da9d7217c978b5dd503a5 · Zeichen 524–727 im Abschnitt

Wechselwirkungen · Sunlenca

Sunlenca 464 mg solution for injection · Abschnitt 4.5 · PDF-Seite 6–7

HOS-148304 · Präparat HOS-099874

6 Medicinal product by Effects on concentrations. Recommendation concerning therapeutic areas Mean percent change in AUC, co-administration with Sunlenca Cmax ERGOT DERIVATIVES Dihydroergotamine Interaction not studied. Caution is warranted when Ergotamine dihydroergotamine or ergotamine, Plasma concentrations of these is co-administered with Sunlenca. medicinal products may be increased when co-administered with lenacapavir. PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS Sildenafil Interaction not studied. Use of PDE-5 inhibitors for Tadalafil pulmonary arterial hypertension: Vardenafil Plasma concentration of PDE-5 Co-administration with tadalafil is inhibitors may be increased when not recommended. co-administered with lenacapavir. Use of PDE-5 inhibitors for erectile dysfunction: Sildenafil: A starting dose of 25 mg is recommended. Vardenafil: No more than 5 mg in a 24-hour period. Tadalafil: • For use as needed: no more than 10 mg every 72 hours • For once daily use: dose not to exceed 2.5 mg CORTICOSTEROIDS (systemic) Cortisone/hydrocortisone Interaction not studied. Co-administration of Sunlenca with Dexamethasone corticosteroids whose exposures Plasma concentrations of are significantly increased by corticosteroids may be increased CYP3A inhibitors can increase the when co-administered with risk for Cushing's syndrome and lenacapavir. adrenal suppression. Initiate with the lowest starting dose and titrate Plasma concentrations of carefully while monitoring for lenacapavir may decrease when co- safety. administered with systemic dexamethasone, which may result Caution is warranted when in loss of therapeutic effect and systemic dexamethasone is development of resistance. co-administered with Sunlenca, particularly for long-term use. Alternative corticosteroids should be considered. HMG-CoA REDUCTASE INHIBITORS Lovastatin Interaction not studied. Initiate lovastatin and simvastatin Simvastatin with the lowest starting dose and Plasma concentrations of these titrate carefully while monitoring medicinal products may be for safety (e.g. myopathy). Atorvastatin increased when co-administered No dose adjustment of atorvastatin with lenacapavir. is required. Pitavastatind,i,l (2 mg single dose; Pitavastatin: No dose adjustment of pitavastatin simultaneous or 3 days after AUC:↔ and rosuvastatin is required. lenacapavir) Cmax:↔ Rosuvastatind,i,m (5 mg single dose) Rosuvastatin: AUC:↑ 31% Cmax:↑ 57% ANTIARRHYTHMICS Digoxin Interaction not studied. Caution is warranted and therapeutic concentration Plasma concentration of digoxin monitoring of digoxin is may be increased when recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cortisone (HOS-114161) tadalafil (HOS-086316) lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) digoxin (HOS-086172) dexamethasone (HOS-084535) sildenafil (HOS-086162) hydrocortisone (HOS-148307) ergotamine (HOS-086154) dihydroergotamine (HOS-086152) pitavastatin (HOS-125743) vardenafil (HOS-086163)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-02-26T15:19:00Z · SHA-256 5e82373c9638ee4d24450180684e7d233b6a19a1b3755e36a56d1822304f7bda · Passage 00e9d7399a80f2d2a9a0f459efd3beda50e916865cbf3466967e4abfe66e160f · Zeichen 6404–11764 im Abschnitt

Wechselwirkungen · Sunlenca

Sunlenca 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 23–24

HOS-148341 · Präparat HOS-099874

23 Medicinal product by therapeutic Effects on concentrations. Recommendation concerning areas Mean percent change in AUC, co-administration with Sunlenca Cmax CORTICOSTEROIDS (systemic) Cortisone/hydrocortisone Interaction not studied. Co-administration of Sunlenca with Dexamethasone corticosteroids whose exposures Plasma concentrations of are significantly increased by corticosteroids may be increased CYP3A inhibitors can increase the when co-administered with risk for Cushing's syndrome and lenacapavir. adrenal suppression. Initiate with the lowest starting dose and titrate Plasma concentrations of carefully while monitoring for lenacapavir may decrease when co- safety. administered with systemic dexamethasone, which may result Caution is warranted when in loss of therapeutic effect and systemic dexamethasone is development of resistance. co-administered with Sunlenca, particularly for long-term use. Alternative corticosteroids should be considered. HMG-CoA REDUCTASE INHIBITORS Lovastatin Interaction not studied. Initiate lovastatin and simvastatin Simvastatin with the lowest starting dose and Plasma concentrations of these titrate carefully while monitoring medicinal products may be for safety (e.g. myopathy). Atorvastatin increased when co-administered No dose adjustment of atorvastatin with lenacapavir. is required. Pitavastatin (2 mg single dose; d,i,l Pitavastatin: No dose adjustment of pitavastatin simultaneous or 3 days after AUC:↔ and rosuvastatin is required. lenacapavir) Cmax:↔ Rosuvastatind,i,m (5 mg single dose) Rosuvastatin: AUC:↑ 31% Cmax:↑ 57% ANTIARRHYTHMICS Digoxin Interaction not studied. Caution is warranted and therapeutic concentration Plasma concentration of digoxin monitoring of digoxin is may be increased when recommended. co-administered with lenacapavir. SEDATIVES/HYPNOTICS Midazolamd,i,n (2.5 mg single dose; Midazolam: Caution is warranted when oral; simultaneous administration) AUC: ↑ 259% midazolam or triazolam, is Cmax: ↑ 94% co-administered with Sunlenca.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cortisone (HOS-114161) lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) digoxin (HOS-086172) dexamethasone (HOS-084535) hydrocortisone (HOS-148307) triazolam (HOS-086168) midazolam (HOS-086167) pitavastatin (HOS-125743)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-02-26T15:19:00Z · SHA-256 5e82373c9638ee4d24450180684e7d233b6a19a1b3755e36a56d1822304f7bda · Passage 04f608f5ff93546fe1f7b83e8a9deb3141b0dd6a2fdcedbdf68a141374323bab · Zeichen 8599–12414 im Abschnitt

Quellenpassagen (8)

Wechselwirkungen · Omnitrope

Wechselwirkungen · Omnitrope

Wechselwirkungen · Advagraf

Wechselwirkungen · Modigraf

Wechselwirkungen · Tacforius

Wechselwirkungen · Sogroya

Wechselwirkungen · Sunlenca

Wechselwirkungen · Sunlenca